Elanco Animal Health reported a revenue of $1,068 million, a 4% increase, and a net loss of $1,096 million, which included a $1,042 million non-cash goodwill impairment charge. Adjusted EPS was $0.18, and adjusted EBITDA reached $214 million. The company is updating its full-year guidance to reflect its third-quarter performance and the impact of foreign exchange rates.
Revenue reached $1,068 million, reflecting a 4% reported growth or 5% excluding foreign exchange impacts.
A reported net loss of $1,096 million was inclusive of a $1,042 million non-cash goodwill impairment charge.
Adjusted EBITDA was $214 million, representing 20.0% of revenue.
Innovation pipeline remains on track with potential blockbuster products Credelio Quattro, Bovaer and Zenrelia.
Elanco is updating its full year 2023 guidance to reflect third quarter outperformance offset by expected unfavorable impact of foreign exchange rates.
Visualization of income flow from segment revenue to net income